SCHEMBL24257514

SCHEMBL24257514

CCOC(=O)CNC(=O)c1ncc(-c2cccnc2)c(C)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
CYP11B1 P15538 3/20 0.44
CYP11B2 P19099 3/20 0.44
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
PPID Q08752 2/20 0.43
MEN1 O00255 2/20 0.43
EPHX1 P07099 1/20 0.43
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CYP19A1 P11511 1/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.40
LRRK2 Q5S007 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546860 1.00 ALDH1A1 (0.48) ALDH1A1CYP11B1CYP11B2KMT2AL3MBTL1
SCHEMBL30453137 1.00 ALDH1A1 (0.48) ALDH1A1CYP11B1CYP11B2KMT2AL3MBTL1
SCHEMBL30452770 0.86 VEGFA (0.49) ALDH1A1KMT2AL3MBTL1PPIDMEN1
SCHEMBL24257548 0.86 EGLN1 (0.46) KMT2AL3MBTL1PPIDMEN1KDM4E
SCHEMBL30452640 0.86 EGLN1 (0.46) KMT2AL3MBTL1PPIDMEN1KDM4E
SCHEMBL24257835 0.86 VEGFA (0.49) ALDH1A1KMT2AL3MBTL1PPIDMEN1
SCHEMBL24257686 0.85 GAA (0.48) ALDH1A1KMT2AL3MBTL1PPIDMEN1
SCHEMBL24257806 0.85 EGLN1 (0.44) KMT2AL3MBTL1PPIDMEN1SMN1; SMN2
SCHEMBL30452826 0.85 GAA (0.48) ALDH1A1KMT2AL3MBTL1PPIDMEN1
SCHEMBL24257792 0.85 EGLN1 (0.46) ALDH1A1KMT2AL3MBTL1PPIDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALDH1A1 1362/4885CYP11B1 809/4885CYP11B2 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.